MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

MiNK Therapeutics (NASDAQ:INKT) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other research firms also recently weighed in on INKT. Weiss Ratings upgraded shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research report on Monday, May 18th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MiNK Therapeutics presently has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Down 3.2%

Shares of INKT stock opened at $11.00 on Wednesday. MiNK Therapeutics has a fifty-two week low of $8.48 and a fifty-two week high of $18.17. The stock has a market cap of $54.78 million, a P/E ratio of -3.87 and a beta of 0.48. The business has a fifty day simple moving average of $11.34 and a 200-day simple moving average of $11.23.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). On average, sell-side analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC increased its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities and Exchange Commission. 2.87% of the stock is currently owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.